Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Edgewise Therapeutics, Inc. (EWTX)
USD41.27
-4.14 (-9.12%)
US NASDAQ Healthcare Biotechnology
Address
3415 Colorado Avenue 80303
Boulder, CO, US
Boulder, CO, US
CEO
Kevin Koch
Website
edgewisetx.com
IPO
2021-03-26
CIK 1710072 ISIN US28036F1057
Description
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD41.27
-4.14 (-9.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.30
Float Shares
77.20M
Free Float %
72.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.15% | -9.05% | +5.30% | +13.80% | +63.25% | +39.24% | +133.20% | +272.82% | +31.31% | +15.20% | +15.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
41.27
Low
25.00
-39.4%
Consensus
42.00
+1.8%
Median
45.50
+10.2%
High
52.00
+26.0%
DCF (Unlevered)
0.50
-98.8%
DCF (Levered)
0.56
-98.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
52.00
+26.0%
|
| Last Quarter | 4 |
42.00
+1.8%
|
| Last Year | 5 |
37.60
-8.9%
|
| All Time | 11 |
42.82
+3.8%
|
Quality scores
Altman Z-Score
85.91
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-12.4% Q1'26: -7.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +8,435.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+11.4% Q1'26: +12.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 8 EPS Ana. |
Dec 2027 7 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
2.27M
1.43M – 3.82M
|
14.47M
2.44M – 36.54M
+536.5% YoY
|
127.52M
80.30M – 214.18M
+781.5% YoY
|
330.28M
207.97M – 554.74M
+159.0% YoY
|
744.99M
469.11M – 1.25B
+125.6% YoY
|
| EBITDA |
-156.54M
|
-165.53M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-158.83M
|
-167.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-133.81M
est: -140.47M (+4.7%)
|
-167.80M
est: -165.27M (-1.5%)
|
-220.95M
-243.59M – -179.75M
-33.7% YoY
|
-258.27M
-292.26M – -178.21M
-16.9% YoY
|
-215.06M
-236.09M – -122.11M
+16.7% YoY
|
-77.93M
-146.79M – -40.42M
+63.8% YoY
|
118.08M
61.23M – 222.40M
+251.5% YoY
|
| SGA |
31.87M
|
40.02M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.45
est: -1.49 (+2.6%)
|
-1.63
est: -1.60 (-2.2%)
|
-2.05
-2.37 – -1.75
-28.6% YoY
|
-2.28
-2.84 – -1.73
-10.9% YoY
|
-1.72
-2.29 – -1.19
+24.2% YoY
|
-0.76
-1.43 – -0.39
+56.1% YoY
|
1.15
0.59 – 2.16
+251.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
56
Total invested
182.16M
Insider transactions (90d)
2
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors LLC | 13.68M | 27.80% | — | 13.68M | — | 10.00 | IA | Delaware | 2021-04-08 | ↗ |
| 2 | OrbiMed Capital GP VI LLC | 13.36M | 27.10% | — | 13.36M | — | 10.00 | OO | Delaware | 2021-04-08 | ↗ |
| 3 | Peter Kolchinsky | 8.91M | 9.60% | — | 8.91M | — | — | HC, IN | Delaware | 2024-01-29 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 8.91M | 9.60% | — | 8.91M | — | — | PN | Delaware | 2024-01-29 | ↗ |
| 5 | RA Capital Management, L.P. | 8.91M | 9.60% | — | 8.91M | — | — | IA, PN | Delaware | 2024-01-29 | ↗ |
| 6 | Rajeev Shah | 8.91M | 9.60% | — | 8.91M | — | — | HC, IN | Delaware | 2024-01-29 | ↗ |
| 7 | Abigail P. Johnson | 7.98M | 12.63% | — | — | 7.98M | — | IN | Delaware | 2022-10-11 | ↗ |
| 8 | FMR LLC | 7.98M | 12.63% | 7.98M | — | 7.98M | — | HC | Delaware | 2022-10-11 | ↗ |
| 9 | (1) BlackRock, Inc. | 6.39M | 6.80% | 6.22M | — | 6.39M | — | HC | Delaware | 2024-11-08 | ↗ |
| 10 | Baker Bros. Advisors (GP) LLC | 5.84M | 6.20% | 5.84M | — | 5.84M | — | HC, OO | Delaware | 2024-11-14 | ↗ |
| 11 | Baker Bros. Advisors LP | 5.84M | 6.20% | 5.84M | — | 5.84M | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 12 | Felix J. Baker | 5.84M | 6.20% | 5.84M | — | 5.84M | — | HC, IN | United States | 2024-11-14 | ↗ |
| 13 | Julian C. Baker | 5.84M | 6.20% | 5.84M | — | 5.84M | — | HC, IN | United States | 2024-11-14 | ↗ |
| 14 | EcoR1 Capital, LLC | 3.49M | 11.00% | — | 3.49M | — | 3.49M | IA, OO | Delaware | 2022-09-26 | ↗ |
| 15 | Oleg Nodelman | 3.49M | 11.00% | — | 3.49M | — | 3.49M | HC, IN | Delaware | 2022-09-26 | ↗ |
| 16 | S | 3.47M | 7.10% | 3.47M | — | 3.47M | — | OO | Delaware | 2021-05-03 | ↗ |
| 17 | U.S. Venture Partners XI, L.P. (“USVP XI”) | 3.47M | 7.10% | 3.47M | — | 3.47M | — | PN | Delaware | 2021-05-03 | ↗ |
| 18 | David Kroin | 3.37M | 5.34% | — | 3.37M | — | — | HC, IN | Delaware | 2022-09-23 | ↗ |
| 19 | Deep Track Biotechnology Master Fund, Ltd. | 3.37M | 5.34% | — | 3.37M | — | — | CO | Delaware | 2022-09-23 | ↗ |
| 20 | Deep Track Capital, LP | 3.37M | 5.34% | — | 3.37M | — | — | IA, OO | Delaware | 2022-09-23 | ↗ |
| 21 | Rose S. Shabet | 3.35M | 7.00% | — | 3.35M | — | — | IN | United States | 2021-04-05 | ↗ |
| 22 | Viking Global Opportunities GP LLC | 3.35M | 7.00% | — | 3.35M | — | — | OO | Delaware | 2021-04-05 | ↗ |
| 23 | EcoR1 Capital Fund Qualified, L.P. | 3.29M | 11.00% | — | 3.29M | — | 3.29M | PN | Delaware | 2022-09-26 | ↗ |
| 24 | Viking Global Investors LP | 2.73M | 5.50% | — | 2.73M | — | 2.73M | PN | Delaware | 2022-02-14 | ↗ |
| 25 | Bihua Chen | 2.59M | 5.26% | — | 2.59M | — | 2.59M | IN | United States | 2021-05-18 | ↗ |
| 26 | Cormorant Asset Management, LP | 2.59M | 5.26% | — | 2.59M | — | 2.59M | PN | Delaware | 2021-05-18 | ↗ |
| 27 | Cormorant Global Healthcare GP, LLC | 1.66M | 3.37% | — | 1.66M | — | 1.66M | OO | Delaware | 2021-05-18 | ↗ |
| 28 | Cormorant Global Healthcare Master Fund, LP | 1.66M | 3.37% | — | 1.66M | — | 1.66M | PN | Cayman Islands | 2021-05-18 | ↗ |
| 29 | Cormorant Private Healthcare Fund III, LP | 852.0K | 1.73% | — | 852.0K | — | 852.0K | PN | Delaware | 2021-05-18 | ↗ |
| 30 | Cormorant Private Healthcare GP III, LLC | 852.0K | 1.73% | — | 852.0K | — | 852.0K | OO | Delaware | 2021-05-18 | ↗ |
| 31 | OrbiMed Genesis GP LLC | 319.6K | 0.70% | — | 319.6K | — | 10.00 | IA | Cayman Islands | 2021-04-08 | ↗ |
| 32 | OrbiMed Capital LLC | 265.6K | 0.50% | 265.6K | — | 265.6K | 10.00 | OO | Cayman Islands | 2021-04-08 | ↗ |
| 33 | 2. | 10.00 | 5.00% | — | 2.45M | — | — | IA, HC, OO | Delaware | 2022-01-13 | ↗ |
| 34 | Citadel Advisors Holdings LP | 6.00 | 4.80% | — | 2.38M | — | 2.38M | HC, PN | Delaware | 2021-07-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
56
-154 vs prev Q
New positions
14
Closed positions
158
Increased
28
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 15.52M +— (+0.0%) | 385.09M +133.4M (+53.0%) | 14.71% -0.077 pp | 7.89% +1.960 pp | USD30.53 -18.7% | 20 qtrs — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 10.43M +— (+0.0%) | 258.78M +89.6M (+53.0%) | 9.89% -0.052 pp | 2.65% +0.567 pp | USD17.46 +42.2% | 8 qtrs — |
| 3 | BLACKROCK, INC. | 6.63M +279.1K (+4.4%) | 164.54M +61.5M (+59.7%) | 6.29% +0.233 pp | 0.00% +0.001 pp | USD26.04 -4.7% | 6 qtrs — |
| 4 | BAKER BROS. ADVISORS LP | 6.58M -730.0K (-10.0%) | 163.18M +44.7M (+37.7%) | 6.23% -0.728 pp | 0.96% +0.099 pp | USD15.69 +58.2% | 20 qtrs — |
| 5 | PARADIGM BIOCAPITAL ADVISORS LP | 6.54M +371.1K (+6.0%) | 162.32M +62.2M (+62.2%) | 6.20% +0.321 pp | 4.14% +1.297 pp | USD19.90 +24.7% | 8 qtrs — |
| 6 | NOVO HOLDINGS A/S | 5.35M +— (+0.0%) | 132.76M +46.0M (+53.0%) | 5.07% -0.027 pp | 10.31% +4.717 pp | USD19.55 +27.0% | 20 qtrs — |
| 7 | BRAIDWELL LP | 5.21M +— (+0.0%) | 129.31M +44.8M (+53.0%) | 4.94% -0.026 pp | 4.14% +1.627 pp | USD19.40 +27.9% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 4.87M +67.7K (+1.4%) | 120.89M +43.0M (+55.1%) | 4.62% +0.040 pp | 0.00% +0.001 pp | USD16.47 +50.7% | 20 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 4.57M -412.5K (-8.3%) | 113.33M +32.5M (+40.2%) | 4.33% -0.416 pp | 0.05% +0.014 pp | USD21.90 +13.3% | 20 qtrs — |
| 10 | SIREN, L.L.C. | 4.53M +632.9K (+16.2%) | 112.41M +49.2M (+77.8%) | 4.29% +0.581 pp | 3.35% +0.880 pp | USD19.34 +28.3% | 6 qtrs — |
| 11 | PERCEPTIVE ADVISORS LLC | 4.46M +662.1K (+17.4%) | 110.62M +49.1M (+79.7%) | 4.23% +0.609 pp | 1.97% +0.194 pp | USD21.55 +15.2% | 9 qtrs — |
| 12 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.19M +2.0M (+88.1%) | 104.00M +67.9M (+187.8%) | 3.97% +1.850 pp | 0.71% +0.448 pp | USD20.84 +19.1% | 9 qtrs — |
| 13 | CORMORANT ASSET MANAGEMENT, LP | 3.29M -725.0K (-18.1%) | 81.52M +16.5M (+25.3%) | 3.11% -0.707 pp | 3.77% -0.719 pp | USD22.70 +9.3% | 20 qtrs — |
| 14 | MORGAN STANLEY | 2.91M +2.0M (+234.7%) | 72.23M +58.1M (+412.1%) | 2.76% +1.931 pp | 0.00% +0.004 pp | USD22.31 +11.3% | 19 qtrs — |
| 15 | UBS GROUP AG | 2.12M +2.0M (+1,755.0%) | 52.54M +50.7M (+2,738.0%) | 2.01% +1.898 pp | 0.01% +0.008 pp | USD24.65 +0.7% | 8 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.75M +28.6K (+1.7%) | 43.34M +15.5M (+55.5%) | 1.66% +0.019 pp | 0.00% +0.001 pp | USD15.42 +61.0% | 19 qtrs — |
| 17 | STATE STREET CORP | 1.72M +17.4K (+1.0%) | 42.62M +15.0M (+54.6%) | 1.63% +0.008 pp | 0.00% +0.001 pp | USD16.25 +52.7% | 19 qtrs — |
| 18 | BIOIMPACT CAPITAL LLC | 1.66M -65.5K (-3.8%) | 41.08M +13.2M (+47.2%) | 1.57% -0.071 pp | 4.70% +0.131 pp | USD18.27 +35.9% | 8 qtrs — |
| 19 | FIRST LIGHT ASSET MANAGEMENT, LLC | 1.57M +158.7K (+11.2%) | 39.05M +16.1M (+70.1%) | 1.49% +0.143 pp | 2.99% +0.822 pp | USD24.07 +3.1% | 5 qtrs — |
| 20 | BELLEVUE GROUP AG | 1.53M -1.2M (-44.9%) | 37.93M -7.1M (-15.8%) | 1.45% -1.196 pp | 0.72% -0.217 pp | USD16.34 +51.9% | 7 qtrs — |
| 21 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.50M +— (+0.0%) | 37.22M +12.9M (+53.0%) | 1.42% -0.008 pp | 1.85% +0.202 pp | USD19.87 +24.9% | 5 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 1.47M +1.2M (+359.2%) | 36.60M +31.4M (+602.6%) | 1.40% +1.092 pp | 0.00% +0.002 pp | USD23.90 +3.8% | 18 qtrs — |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.21M +30.5K (+2.6%) | 30.11M +10.9M (+57.0%) | 1.15% +0.023 pp | 0.01% +0.002 pp | USD16.40 +51.3% | 14 qtrs — |
| 24 | AMERICAN CENTURY COMPANIES INC | 1.19M +91.0K (+8.3%) | 29.44M +11.7M (+65.7%) | 1.12% +0.081 pp | 0.01% +0.006 pp | USD19.04 +30.4% | 20 qtrs — |
| 25 | ALLIANCEBERNSTEIN L.P. | 1.04M +958.9K (+1,241.1%) | 25.71M +24.5M (+1,951.8%) | 0.98% +0.909 pp | 0.01% +0.008 pp | USD24.04 +3.2% | 14 qtrs — |
| 26 | SOLEUS CAPITAL MANAGEMENT, L.P. | 910.0K +910.0K (+100.0%) | 22.58M +22.6M (+100.0%) | 0.86% +0.863 pp | 0.83% +0.833 pp | USD24.82 +0.0% | 5 qtrs — |
| 27 | ABRDN PLC | 821.9K +202.1K (+32.6%) | 20.40M +10.3M (+102.9%) | 0.78% +0.188 pp | 0.03% +0.016 pp | USD21.06 +17.9% | 6 qtrs — |
| 28 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 765.7K +— (+0.0%) | 19.00M +6.6M (+53.0%) | 0.73% -0.004 pp | 0.24% +0.053 pp | USD31.67 -21.6% | 20 qtrs — |
| 29 | NORGES BANK | 751.4K +751.4K (+100.0%) | 18.64M +18.6M (+100.0%) | 0.71% +0.712 pp | 0.00% +0.002 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 30 | VICTORY CAPITAL MANAGEMENT INC | 746.6K +247.9K (+49.7%) | 18.53M +10.4M (+129.1%) | 0.71% +0.233 pp | 0.01% +0.006 pp | USD17.23 +44.1% | 5 qtrs — |
| 31 | GOLDMAN SACHS GROUP INC | 718.4K +190.5K (+36.1%) | 17.83M +9.3M (+108.2%) | 0.68% +0.178 pp | 0.00% +0.001 pp | USD16.43 +51.1% | 17 qtrs — |
| 32 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 704.1K -14.1K (-2.0%) | 17.47M +5.8M (+50.0%) | 0.67% -0.017 pp | 0.03% +0.010 pp | USD22.14 +12.1% | 6 qtrs — |
| 33 | FMR LLC | 693.0K +439.6K (+173.5%) | 17.20M +13.1M (+318.5%) | 0.66% +0.416 pp | 0.00% +0.001 pp | USD20.71 +19.8% | 20 qtrs — |
| 34 | MARSHALL WACE, LLP | 681.9K +681.9K (+100.0%) | 16.93M +16.9M (+100.0%) | 0.65% +0.646 pp | 0.02% +0.015 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 35 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 640.4K +640.4K (+100.0%) | 15.89M +15.9M (+100.0%) | 0.61% +0.607 pp | 0.03% +0.027 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 36 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 611.4K +13.8K (+2.3%) | 15.17M +5.5M (+56.5%) | 0.58% +0.010 pp | 0.00% +0.001 pp | USD15.23 +63.0% | 19 qtrs — |
| 37 | EVENTIDE ASSET MANAGEMENT, LLC | 568.3K +— (+0.0%) | 14.10M +4.9M (+53.0%) | 0.54% -0.003 pp | 0.22% +0.069 pp | USD22.00 +12.8% | 4 qtrs — |
| 38 | NORTHERN TRUST CORP | 559.6K -28.2K (-4.8%) | 13.89M +4.4M (+45.6%) | 0.53% -0.030 pp | 0.00% +0.001 pp | USD17.07 +45.4% | 19 qtrs — |
| 39 | CANDRIAM S.C.A. | 501.2K +280.1K (+126.6%) | 12.44M +8.9M (+246.7%) | 0.48% +0.264 pp | 0.06% +0.043 pp | USD18.32 +35.5% | 14 qtrs — |
| 40 | OPALEYE MANAGEMENT INC. | 500.0K +— (+0.0%) | 12.41M +4.3M (+53.0%) | 0.47% -0.003 pp | 1.64% +0.490 pp | USD9.57 +159.4% | 16 qtrs — |
| 41 | SOFINNOVA INVESTMENTS, INC. | 437.8K -82.4K (-15.8%) | 10.86M +2.4M (+28.8%) | 0.42% -0.081 pp | 0.47% +0.007 pp | USD16.26 +52.6% | 7 qtrs — |
| 42 | PARKMAN HEALTHCARE PARTNERS LLC | 427.7K -122.5K (-22.3%) | 10.61M +1.7M (+18.9%) | 0.41% -0.119 pp | 1.01% +0.080 pp | USD12.47 +99.0% | 14 qtrs — |
| 43 | D. E. SHAW & CO., INC. | 394.7K -282.9K (-41.7%) | 9.79M -1.2M (-10.9%) | 0.37% -0.272 pp | 0.01% -0.001 pp | USD15.44 +60.8% | 9 qtrs — |
| 44 | BARCLAYS PLC | 372.7K +253.4K (+212.3%) | 9.25M +6.1M (+190.4%) | 0.35% +0.240 pp | 0.00% +0.001 pp | USD22.30 +11.3% | 16 qtrs — |
| 45 | STEMPOINT CAPITAL LP | 360.9K +360.9K (+100.0%) | 8.96M +9.0M (+100.0%) | 0.34% +0.342 pp | 1.54% +1.536 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 46 | — | 350.0K +350.0K (+100.0%) | 8.69M +8.7M (+100.0%) | 0.33% +0.332 pp | 3.68% +3.681 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 47 | EVERSEPT PARTNERS, LP | 337.3K -164.9K (-32.8%) | 8.37M +224.9K (+2.8%) | 0.32% -0.159 pp | 0.42% -0.140 pp | USD13.79 +80.0% | 3 qtrs — |
| 48 | QUBE RESEARCH & TECHNOLOGIES LTD | 296.2K -259.5K (-46.7%) | 7.35M -1.7M (-18.5%) | 0.28% -0.249 pp | 0.01% -0.002 pp | USD22.48 +10.4% | 9 qtrs — |
| 49 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 271.4K +138.9K (+104.8%) | 6.73M +4.6M (+213.3%) | 0.26% +0.131 pp | 0.01% +0.007 pp | USD23.58 +5.3% | 5 qtrs — |
| 50 | ALLY BRIDGE GROUP (NY) LLC | 250.0K +250.0K (+100.0%) | 6.20M +6.2M (+100.0%) | 0.24% +0.237 pp | 6.46% +6.463 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 51 | KENNEDY CAPITAL MANAGEMENT LLC | 241.5K -9.1K (-3.6%) | 5.99M +1.9M (+47.4%) | 0.23% -0.010 pp | 0.13% +0.037 pp | USD11.75 +111.2% | 9 qtrs — |
| 52 | SIO CAPITAL MANAGEMENT, LLC | 237.5K -69.7K (-22.7%) | 5.89M +910.6K (+18.3%) | 0.23% -0.068 pp | 0.93% -0.334 pp | USD13.11 +89.3% | 3 qtrs — |
| 53 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 232.3K -107.3K (-31.6%) | 5.76M +255.8K (+4.6%) | 0.22% -0.103 pp | 0.25% +0.021 pp | USD10.77 +130.5% | 12 qtrs — |
| 54 | WOODLINE PARTNERS LP | 224.2K +2.0 (+0.0%) | 5.56M +1.9M (+53.0%) | 0.21% -0.001 pp | 0.02% +0.004 pp | USD20.97 +18.4% | 20 qtrs — |
| 55 | CITIGROUP INC | 223.3K -315.2K (-58.5%) | 5.54M -3.2M (-36.6%) | 0.21% -0.301 pp | 0.00% -0.001 pp | USD14.20 +74.8% | 19 qtrs — |
| 56 | DEUTSCHE BANK AG\ | 214.8K +59.9K (+38.7%) | 5.33M +2.8M (+112.2%) | 0.20% +0.056 pp | 0.00% +0.001 pp | USD24.23 +2.4% | 19 qtrs — |
| 57 | AMERIPRISE FINANCIAL INC | 202.3K +202.3K (+100.0%) | 5.02M +5.0M (+100.0%) | 0.19% +0.192 pp | 0.00% +0.001 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 58 | BANK OF NEW YORK MELLON CORP | 198.6K -5.6K (-2.8%) | 4.93M +1.6M (+48.8%) | 0.19% -0.006 pp | 0.00% +0.000 pp | USD15.69 +58.2% | 19 qtrs — |
| 59 | HIGHVISTA STRATEGIES LLC | 171.1K -37.0K (-17.8%) | 4.25M +871.4K (+25.8%) | 0.16% -0.036 pp | 1.09% +0.266 pp | USD19.58 +26.8% | 6 qtrs — |
| 60 | NUVEEN, LLC | 169.5K -3.2K (-1.9%) | 4.21M +1.4M (+50.1%) | 0.16% -0.004 pp | 0.00% +0.000 pp | USD18.79 +32.1% | 4 qtrs — |
| 61 | DAFNA CAPITAL MANAGEMENT LLC | 159.7K -54.0K (-25.3%) | 3.96M +497.1K (+14.3%) | 0.15% -0.052 pp | 0.92% +0.064 pp | USD9.92 +150.2% | 16 qtrs — |
| 62 | BALYASNY ASSET MANAGEMENT L.P. | 151.9K +151.9K (+100.0%) | 3.77M +3.8M (+100.0%) | 0.14% +0.144 pp | 0.00% +0.005 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 63 | JPMORGAN CHASE & CO | 146.0K +77.3K (+112.5%) | 3.62M +2.5M (+225.1%) | 0.14% +0.073 pp | 0.00% +0.000 pp | USD23.35 +6.3% | 19 qtrs — |
| 64 | SCHRODER INVESTMENT MANAGEMENT GROUP | 145.3K -5.8K (-3.8%) | 3.57M +1.2M (+49.9%) | 0.14% -0.006 pp | 0.00% +0.001 pp | USD20.23 +22.7% | 5 qtrs — |
| 65 | NEUBERGER BERMAN GROUP LLC | 127.1K -92.5K (-42.1%) | 3.15M -407.8K (-11.4%) | 0.12% -0.089 pp | 0.00% 0.000 pp | USD18.01 +37.8% | 4 qtrs — |
| 66 | MILLENNIUM MANAGEMENT LLC | 126.4K -599.0K (-82.6%) | 3.14M -8.6M (-73.3%) | 0.12% -0.571 pp | 0.00% -0.004 pp | USD16.22 +53.0% | 10 qtrs — |
| 67 | JAIN GLOBAL LLC | 113.9K +113.9K (+100.0%) | 2.83M +2.8M (+100.0%) | 0.11% +0.108 pp | 0.01% +0.014 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 68 | WELLINGTON MANAGEMENT GROUP LLP | 111.4K -3.1K (-2.7%) | 2.76M +906.4K (+48.8%) | 0.11% -0.004 pp | 0.00% +0.000 pp | USD27.87 -10.9% | 20 qtrs — |
| 69 | QUANTUM PRIVATE WEALTH, LLC | 106.0K +150.0 (+0.1%) | 2.63M +913.7K (+53.2%) | 0.10% 0.000 pp | 0.77% +0.266 pp | USD14.15 +75.4% | 17 qtrs — |
| 70 | SWISS NATIONAL BANK | 103.9K +2.0K (+2.0%) | 2.58M +925.5K (+56.0%) | 0.10% +0.001 pp | 0.00% +0.001 pp | USD14.61 +69.9% | 9 qtrs — |
| 71 | EXOME ASSET MANAGEMENT LLC | 100.0K -73.4K (-42.3%) | 2.48M -330.5K (-11.7%) | 0.09% -0.070 pp | 1.19% -0.516 pp | USD19.58 +26.8% | 6 qtrs — |
| 72 | UBS ASSET MANAGEMENT AMERICAS INC | 98.1K -41.0K (-29.5%) | 2.43M +177.0K (+7.8%) | 0.09% -0.040 pp | 0.00% +0.000 pp | USD23.85 +4.1% | 9 qtrs — |
| 73 | ADAR1 CAPITAL MANAGEMENT, LLC | 91.0K +51.0K (+127.5%) | 2.26M +1.6M (+248.0%) | 0.09% +0.048 pp | 0.17% +0.105 pp | USD21.63 +14.7% | 8 qtrs — |
| 74 | NEW YORK STATE COMMON RETIREMENT FUND | 88.9K +5.5K (+6.6%) | 2.21M +853.6K (+63.1%) | 0.08% +0.005 pp | 0.00% +0.001 pp | USD18.30 +35.6% | 19 qtrs — |
| 75 | SG AMERICAS SECURITIES, LLC | 88.7K +78.8K (+797.9%) | 2.20M +2.0M (+1,276.3%) | 0.08% +0.075 pp | 0.00% +0.002 pp | USD23.86 +4.0% | 15 qtrs — |
| 76 | ALPS ADVISORS INC | 86.9K +35.8K (+70.1%) | 2.16M +1.3M (+160.2%) | 0.08% +0.034 pp | 0.01% +0.008 pp | USD18.51 +34.1% | 13 qtrs — |
| 77 | RHUMBLINE ADVISERS | 85.1K -19.8K (-18.8%) | 2.11M +410.8K (+24.2%) | 0.08% -0.019 pp | 0.00% +0.000 pp | USD14.93 +66.2% | 17 qtrs — |
| 78 | FEDERATED HERMES, INC. | 82.1K +22.8K (+38.5%) | 2.04M +1.1M (+112.0%) | 0.08% +0.021 pp | 0.00% +0.002 pp | USD16.37 +51.6% | 7 qtrs — |
| 79 | JUMP FINANCIAL, LLC | 79.9K -910.0 (-1.1%) | 1.98M +672.1K (+51.3%) | 0.08% -0.001 pp | 0.02% +0.009 pp | USD13.11 +89.3% | 6 qtrs — |
| 80 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 78.2K +1.7K (+2.2%) | 1.94M +700.1K (+56.4%) | 0.07% +0.001 pp | 0.00% +0.000 pp | USD18.24 +36.1% | 7 qtrs — |
| 81 | CAPTION MANAGEMENT, LLC | 77.5K +77.5K (+100.0%) | 1.92M +1.9M (+100.0%) | 0.07% +0.074 pp | 0.01% +0.013 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 82 | WELLS FARGO & COMPANY/MN | 75.4K +33.2K (+78.8%) | 1.87M +1.2M (+173.5%) | 0.07% +0.031 pp | 0.00% +0.000 pp | USD20.48 +21.2% | 17 qtrs — |
| 83 | INVESCO LTD. | 75.4K +9.4K (+14.2%) | 1.87M +800.6K (+74.7%) | 0.07% +0.009 pp | 0.00% +0.000 pp | USD20.51 +21.0% | 17 qtrs — |
| 84 | CITADEL ADVISORS LLC | 73.5K +27.4K (+59.4%) | 1.82M +1.1M (+143.9%) | 0.07% +0.026 pp | 0.00% +0.000 pp | USD23.63 +5.0% | 13 qtrs — |
| 85 | DEKABANK DEUTSCHE GIROZENTRALE | 80.0K +— (+0.0%) | 1.56M +16.0K (+1.0%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD9.75 +154.6% | 17 qtrs — |
| 86 | SCHONFELD STRATEGIC ADVISORS LLC | 59.3K +7.3K (+14.1%) | 1.47M +628.9K (+74.6%) | 0.06% +0.007 pp | 0.01% +0.002 pp | USD24.25 +2.4% | 12 qtrs — |
| 87 | DLD ASSET MANAGEMENT, LP | 57.6K +57.6K (+100.0%) | 1.43M +1.4M (+100.0%) | 0.05% +0.055 pp | 0.11% +0.106 pp | USD24.82 +0.0% | 1 qtrs NEW |
| 88 | PRICE T ROWE ASSOCIATES INC /MD/ | 57.3K +5.9K (+11.5%) | 1.42M +588.0K (+70.5%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD21.64 +14.7% | 16 qtrs — |
| 89 | XTX TOPCO LTD | 55.6K +55.6K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.05% +0.053 pp | 0.04% +0.036 pp | USD24.82 +0.0% | 3 qtrs — |
| 90 | HIGHMARK WEALTH MANAGEMENT LLC | 53.2K +— (+0.0%) | 1.32M +457.1K (+53.0%) | 0.05% 0.000 pp | 0.54% +0.158 pp | USD13.22 +87.7% | 5 qtrs — |
| 91 | LEGAL & GENERAL GROUP PLC | 52.7K -3.2K (-5.7%) | 1.31M +401.6K (+44.3%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD17.81 +39.4% | 19 qtrs — |
| 92 | TWO SIGMA INVESTMENTS, LP | 50.8K +24.6K (+93.6%) | 1.26M +835.8K (+196.2%) | 0.05% +0.023 pp | 0.00% +0.001 pp | USD20.38 +21.8% | 10 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 50.4K -401.0 (-0.8%) | 1.25M +426.6K (+51.8%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD14.44 +71.9% | 19 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.60
Neutral
Ratio by volume
0.49
Bearish
Buys
3
Sells
5
Shares acquired
79.0K
Shares disposed
162.6K
Cash buys
—
Cash sales
3.00
Net activity
-83,553
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Donovan Joanne M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,000 | 7.08 | 354.0K | 75,000 | D | ↗ |
| 2026-05-04 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 5,230 | 31.29 | 163.7K | 4,367 | D | ↗ |
| 2026-04-01 | Fox Jonathan C | Director | A-Award | A | Common Stock | 339 | 0.00 | — | 24,514 | D | ↗ |
| 2026-04-01 | Donovan Joanne M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 28,662 | 7.08 | 202.9K | 125,000 | D | ↗ |
| 2026-03-31 | Donovan Joanne M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 21,338 | 7.08 | 151.1K | 153,662 | D | ↗ |
| 2026-03-27 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 9,623 | 30.98 | 298.1K | 16,332 | D | ↗ |
| 2026-01-21 | Edris Badreddin | Director | M-Exempt | D | Stock Option (Right to Buy) | 17,236 | 0.64 | 11.0K | 0 | D | ↗ |
| 2026-01-02 | Fox Jonathan C | Director | A-Award | A | Common Stock | 473 | 0.00 | — | 24,175 | D | ↗ |
| 2025-11-19 | Martin Christopher Nathan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-12 | Russell Alan J | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 0.18 | 18.0K | 1,147,365 | D | ↗ |
| 2025-11-11 | Fox Jonathan C | Director | P-Purchase | A | Common Stock | 10,700 | 18.64 | 199.4K | 23,702 | D | ↗ |
| 2025-11-10 | Nofi Michael | Officer | A-Award | A | Stock Options (Right to buy) | 262,500 | 18.28 | 4.80M | 262,500 | D | ↗ |
| 2025-10-01 | Fox Jonathan C | Director | A-Award | A | Common Stock | 728 | 0.00 | — | 13,002 | D | ↗ |
| 2025-08-26 | Russell Alan J | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 0.18 | 18.0K | 1,247,365 | D | ↗ |
| 2025-08-12 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 1,907 | 13.39 | 25.5K | 23,400 | D | ↗ |
| 2025-08-12 | MOORE JOHN R | Officer | A-Award | A | Restricted Stock Units | 26,875 | 0.00 | — | 26,875 | D | ↗ |
| 2025-08-12 | KOCH KEVIN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 525,000 | 13.39 | 7.03M | 525,000 | D | ↗ |
| 2025-08-12 | Donovan Joanne M. | Officer | M-Exempt | D | Restricted Stock Units | 5,781 | 0.00 | — | 17,344 | D | ↗ |
| 2025-08-12 | Derakhshan Behrad | Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 13.39 | 2.41M | 180,000 | D | ↗ |
| 2025-08-12 | Carruthers R Michael | Officer | A-Award | A | Restricted Stock Units | 26,875 | 0.00 | — | 26,875 | D | ↗ |
| 2025-08-12 | Blaustein Robert | Officer | A-Award | A | Stock Options (Right to buy) | 105,000 | 13.39 | 1.41M | 105,000 | D | ↗ |
| 2025-07-01 | Fox Jonathan C | Director | A-Award | A | Common Stock | 858 | 0.00 | — | 12,274 | D | ↗ |
| 2025-06-16 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-06-16 | ROOT JONATHAN D | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-06-16 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-06-16 | Fox Jonathan C | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-06-16 | Edris Badreddin | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-06-16 | Brege Laura | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 14.68 | 440.4K | 30,000 | D | ↗ |
| 2025-05-02 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 1,551 | 16.45 | 25.5K | 18,521 | D | ↗ |
| 2025-05-02 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 1,930 | 16.45 | 31.8K | 6,531 | D | ↗ |
| 2025-05-02 | KOCH KEVIN | Director / Officer | S-Sale | D | Common Stock | 4,276 | 16.45 | 70.4K | 20,619 | D | ↗ |
| 2025-05-02 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 5,187 | 16.45 | 85.3K | 21,588 | D | ↗ |
| 2025-05-02 | Derakhshan Behrad | Officer | S-Sale | D | Common Stock | 1,691 | 16.45 | 27.8K | 20,355 | D | ↗ |
| 2025-05-02 | Carruthers R Michael | Officer | S-Sale | D | Common Stock | 1,314 | 16.45 | 21.6K | 81,014 | D | ↗ |
| 2025-05-01 | Russell Alan J | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,209 | 0.00 | — | 0 | D | ↗ |
| 2025-05-01 | MOORE JOHN R | Officer | M-Exempt | A | Common Stock | 5,209 | 0.00 | — | 8,461 | D | ↗ |
| 2025-05-01 | KOCH KEVIN | Director / Officer | M-Exempt | A | Common Stock | 10,417 | 0.00 | — | 24,895 | D | ↗ |
| 2025-05-01 | Donovan Joanne M. | Officer | M-Exempt | A | Common Stock | 10,417 | 0.00 | — | 26,775 | D | ↗ |
| 2025-05-01 | Derakhshan Behrad | Officer | M-Exempt | A | Common Stock | 5,209 | 0.00 | — | 22,046 | D | ↗ |
| 2025-05-01 | Carruthers R Michael | Officer | M-Exempt | A | Common Stock | 5,209 | 0.00 | — | 82,328 | D | ↗ |
| 2025-04-03 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock | 124,193 | 20.13 | 2.50M | 443,792 | I | ↗ |
| 2025-04-03 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 372,578 | 20.13 | 7.50M | 14,809,075 | I | ↗ |
| 2025-04-01 | Fox Jonathan C | Director | A-Award | A | Common Stock | 559 | 0.00 | — | 11,416 | D | ↗ |
| 2025-03-07 | Russell Alan J | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 200 | 0.18 | 36.00 | 1,456,580 | D | ↗ |
| 2025-03-07 | KOCH KEVIN | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100 | 0.18 | 18.00 | 41,545 | D | ↗ |
| 2025-02-06 | Russell Alan J | Director / Officer | M-Exempt | A | Common Stock | 1,200 | 0.18 | 216.00 | 16,063 | D | ↗ |
| 2025-02-06 | KOCH KEVIN | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 900 | 0.18 | 162.00 | 41,645 | D | ↗ |
| 2025-02-05 | Russell Alan J | Director / Officer | M-Exempt | A | Common Stock | 8,015 | 0.18 | 1.4K | 22,878 | D | ↗ |
| 2025-02-05 | KOCH KEVIN | Director / Officer | S-Sale | D | Common Stock | 8,636 | 30.03 | 259.3K | 14,478 | D | ↗ |
| 2025-02-05 | Derakhshan Behrad | Officer | M-Exempt | A | Common Stock | 10,000 | 1.93 | 19.3K | 26,837 | D | ↗ |
| 2025-01-28 | Donovan Joanne M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 7.08 | 177.0K | 175,000 | D | ↗ |
| 2025-01-21 | Blaustein Robert | Officer | A-Award | A | Stock Options (Right to buy) | 160,000 | 27.39 | 4.38M | 160,000 | D | ↗ |
| 2024-12-30 | Russell Alan J | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 0.18 | 18.0K | 1,356,780 | D | ↗ |
| 2024-12-24 | Semigran Marc | Officer | S-Sale | D | Common Stock | 27,980 | 29.66 | 829.9K | 8,445 | D | ↗ |
| 2024-10-11 | Carruthers R Michael | Officer | M-Exempt | D | Stock Option (Right to Buy) | 70,000 | 0.71 | 49.7K | 127,122 | D | ↗ |
| 2024-09-23 | MOORE JOHN R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,922 | 0.71 | 14.9K | 41,636 | D | ↗ |
| 2024-09-20 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 815 | 29.51 | 24.0K | 12,719 | D | ↗ |
| 2024-09-20 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 50,000 | 28.37 | 1.42M | 3,252 | D | ↗ |
| 2024-09-20 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 7,162 | 28.29 | 202.6K | 14,538 | D | ↗ |
| 2024-09-20 | Derakhshan Behrad | Officer | M-Exempt | A | Common Stock | 42,068 | 1.93 | 81.2K | 57,189 | D | ↗ |
| 2024-09-20 | Carruthers R Michael | Officer | S-Sale | D | Common Stock | 50,000 | 28.55 | 1.43M | 6,904 | D | ↗ |
| 2024-08-12 | Semigran Marc | Officer | A-Award | A | Restricted Stock Units | 23,125 | 0.00 | — | 23,125 | — | ↗ |
| 2024-08-12 | Russell Alan J | Director / Officer | A-Award | A | Restricted Stock Units | 23,125 | 0.00 | — | 23,125 | — | ↗ |
| 2024-08-12 | MOORE JOHN R | Officer | A-Award | A | Restricted Stock Units | 23,125 | 0.00 | — | 23,125 | — | ↗ |
| 2024-08-12 | KOCH KEVIN | Director / Officer | A-Award | A | Restricted Stock Units | 71,875 | 0.00 | — | 71,875 | — | ↗ |
| 2024-08-12 | Donovan Joanne M. | Officer | A-Award | A | Stock Option (Right to Buy) | 138,750 | 17.05 | 2.37M | 138,750 | — | ↗ |
| 2024-08-12 | Derakhshan Behrad | Officer | A-Award | A | Stock Option (Right to Buy) | 138,750 | 17.05 | 2.37M | 138,750 | — | ↗ |
| 2024-08-12 | Carruthers R Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 138,750 | 17.05 | 2.37M | 138,750 | — | ↗ |
| 2024-06-10 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Options (Right to buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-06-10 | ROOT JONATHAN D | Director | A-Award | A | Stock Option (Right to Buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-06-10 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-06-10 | Fox Jonathan C | Director | A-Award | A | Stock Option (Right to Buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-06-10 | Edris Badreddin | Director | A-Award | A | Stock Option (Right to Buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-06-10 | Brege Laura | Director | A-Award | A | Stock Option (Right to Buy) | 20,594 | 17.13 | 352.8K | 20,594 | — | ↗ |
| 2024-05-06 | Morris Arlene | Director | A-Award | A | Stock Options (Right to buy) | 34,311 | 20.34 | 697.9K | 34,311 | — | ↗ |
| 2024-05-02 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 1,576 | 18.91 | 29.8K | 7,238 | — | ↗ |
| 2024-05-02 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 1,956 | 18.91 | 37.0K | 3,252 | — | ↗ |
| 2024-05-02 | KOCH KEVIN | Director / Officer | S-Sale | D | Common Stock | 3,152 | 18.91 | 59.6K | 14,478 | — | ↗ |
| 2024-05-02 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 3,682 | 18.91 | 69.6K | 19,897 | — | ↗ |
| 2024-05-02 | Derakhshan Behrad | Officer | S-Sale | D | Common Stock | 1,718 | 18.91 | 32.5K | 13,422 | — | ↗ |
| 2024-05-02 | Carruthers R Michael | Officer | S-Sale | D | Common Stock | 2,157 | 18.91 | 40.8K | 35,230 | — | ↗ |
| 2024-05-01 | Russell Alan J | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,208 | 0.00 | — | 5,209 | — | ↗ |
| 2024-05-01 | MOORE JOHN R | Officer | M-Exempt | D | Restricted Stock Units | 5,208 | 0.00 | — | 5,209 | — | ↗ |
| 2024-05-01 | KOCH KEVIN | Director / Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 10,417 | — | ↗ |
| 2024-05-01 | Donovan Joanne M. | Officer | M-Exempt | D | Restricted Stock Units | 10,417 | 0.00 | — | 10,417 | — | ↗ |
| 2024-05-01 | Derakhshan Behrad | Officer | M-Exempt | D | Restricted Stock Units | 5,208 | 0.00 | — | 5,209 | — | ↗ |
| 2024-05-01 | Carruthers R Michael | Officer | M-Exempt | A | Common Stock | 5,208 | 0.00 | — | 37,387 | — | ↗ |
| 2024-02-09 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 8,029 | 20.01 | 160.7K | 0 | — | ↗ |
| 2024-02-09 | Derakhshan Behrad | Officer | S-Sale | D | Common Stock | 4,800 | 20.04 | 96.2K | 7,020 | — | ↗ |
| 2024-02-08 | MOORE JOHN R | Officer | M-Exempt | A | Common Stock | 3,813 | 1.93 | 7.4K | 3,813 | — | ↗ |
| 2024-02-08 | Derakhshan Behrad | Officer | M-Exempt | A | Common Stock | 4,600 | 1.93 | 8.9K | 11,620 | — | ↗ |
| 2024-02-07 | MOORE JOHN R | Officer | M-Exempt | A | Common Stock | 17,993 | 1.93 | 34.7K | 17,993 | — | ↗ |
| 2024-02-07 | Derakhshan Behrad | Officer | S-Sale | D | Common Stock | 600 | 20.00 | 12.0K | 7,020 | — | ↗ |
| 2024-01-23 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock | 454,545 | 11.00 | 5.00M | 14,436,497 | — | ↗ |
| 2024-01-23 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 454,545 | 11.00 | 5.00M | 14,436,497 | — | ↗ |
| 2024-01-23 | Carruthers R Michael | Officer | M-Exempt | D | Stock Option (Right to Buy) | 90,000 | 1.93 | 173.7K | 137,058 | — | ↗ |
| 2023-12-27 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 8,497 | 10.50 | 89.2K | 0 | — | ↗ |
| 2023-12-26 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 172,585 | 9.33 | 1.61M | 3,606 | — | ↗ |
| 2023-12-26 | Fox Jonathan C | Director | P-Purchase | A | Common Stock | 10,857 | 9.30 | 101.0K | 10,857 | — | ↗ |
| 2023-08-17 | Semigran Marc | Officer | A-Award | A | Stock Option (Right to Buy) | 133,333 | 7.08 | 944.0K | 133,333 | — | ↗ |
| 2023-08-17 | Russell Alan J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.08 | 1.42M | 200,000 | — | ↗ |
| 2023-08-17 | MOORE JOHN R | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.08 | 1.42M | 200,000 | — | ↗ |
| 2023-08-17 | KOCH KEVIN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 7.08 | 4.25M | 600,000 | — | ↗ |
| 2023-08-17 | Donovan Joanne M. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.08 | 1.42M | 200,000 | — | ↗ |
| 2023-08-17 | Derakhshan Behrad | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 7.08 | 1.56M | 220,000 | — | ↗ |
| 2023-08-17 | Carruthers R Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.08 | 1.42M | 200,000 | — | ↗ |
| 2023-06-22 | Carruthers R Michael | Officer | M-Exempt | D | Stock Options (Right to buy) | 10,000 | 0.71 | 7.1K | 197,122 | — | ↗ |
| 2023-06-12 | Thompson Peter A. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 22,123 | 9.55 | 211.3K | 22,123 | — | ↗ |
| 2023-06-12 | ROOT JONATHAN D | Director | A-Award | A | Stock Option (Right to Buy) | 22,123 | 9.55 | 211.3K | 22,123 | — | ↗ |
| 2023-06-12 | Fox Jonathan C | Director | A-Award | A | Stock Option (Right to Buy) | 22,123 | 9.55 | 211.3K | 22,123 | — | ↗ |
| 2023-06-12 | Edris Badreddin | Director | A-Award | A | Stock Option (Right to Buy) | 22,123 | 9.55 | 211.3K | 22,123 | — | ↗ |
| 2023-06-12 | Brege Laura | Director | A-Award | A | Stock Option (Right to Buy) | 22,123 | 9.55 | 211.3K | 22,123 | — | ↗ |
| 2023-05-02 | Russell Alan J | Director / Officer | S-Sale | D | Common Stock | 1,602 | 8.90 | 14.3K | 176,191 | — | ↗ |
| 2023-05-02 | MOORE JOHN R | Officer | S-Sale | D | Common Stock | 1,897 | 8.90 | 16.9K | 6,565 | — | ↗ |
| 2023-05-02 | KOCH KEVIN | Director / Officer | S-Sale | D | Common Stock | 3,203 | 8.90 | 28.5K | 7,213 | — | ↗ |
| 2023-05-02 | Donovan Joanne M. | Officer | S-Sale | D | Common Stock | 3,254 | 8.90 | 29.0K | 9,960 | — | ↗ |
| 2023-05-02 | Derakhshan Behrad | Officer | S-Sale | D | Common Stock | 1,747 | 8.90 | 15.6K | 7,020 | — | ↗ |
| 2023-05-02 | Carruthers R Michael | Officer | S-Sale | D | Common Stock | 1,336 | 8.90 | 11.9K | 16,126 | — | ↗ |
| 2023-05-01 | Russell Alan J | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,208 | 0.00 | — | 10,417 | — | ↗ |
| 2023-05-01 | MOORE JOHN R | Officer | M-Exempt | A | Common Stock | 5,208 | 0.00 | — | 8,462 | — | ↗ |
| 2023-05-01 | KOCH KEVIN | Director / Officer | M-Exempt | A | Common Stock | 10,416 | 0.00 | — | 10,416 | — | ↗ |
| 2023-05-01 | Donovan Joanne M. | Officer | M-Exempt | A | Common Stock | 10,416 | 0.00 | — | 13,214 | — | ↗ |
| 2023-05-01 | Derakhshan Behrad | Officer | M-Exempt | A | Common Stock | 5,208 | 0.00 | — | 8,767 | — | ↗ |
| 2023-05-01 | Carruthers R Michael | Officer | M-Exempt | D | Restricted Stock Units | 5,208 | 0.00 | — | 10,417 | — | ↗ |
| 2023-03-03 | Fox Jonathan C | — | A-Award | A | Stock Option (Right to Buy) | 43,731 | 9.43 | 412.4K | 43,731 | — | ↗ |
| 2023-03-02 | Fox Jonathan C | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | Semigran Marc | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2022-12-19 | Semigran Marc | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | MOORE JOHN R | Director | S-Sale | D | Common Stock | 4,730 | 9.76 | 46.2K | 3,000 | — | ↗ |
| 2022-09-16 | Thompson Peter A. | Director / 10% Owner | P-Purchase | A | Common Stock | 484,496 | 10.32 | 5.00M | 13,981,952 | — | ↗ |
| 2022-09-16 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 484,496 | 10.32 | 5.00M | 13,981,952 | — | ↗ |
| 2022-09-14 | Novo Holdings A/S | 10% Owner | P-Purchase | A | COMMON STOCK | 484,496 | 10.32 | 5.00M | 6,071,703 | — | ↗ |
| 2022-09-06 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,730 | 0.00 | — | 127,727 | — | ↗ |
| 2022-08-08 | Russell Alan J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2022-08-08 | MOORE JOHN R | Director | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-08-08 | KOCH KEVIN | Director | A-Award | A | Stock Option (Right to Buy) | 550,000 | 0.00 | — | 550,000 | — | ↗ |
| 2022-08-08 | Donovan Joanne M. | Director | A-Award | A | Stock Option (Right to Buy) | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2022-08-08 | Derakhshan Behrad | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-08-08 | Carruthers R Michael | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-08-03 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 4,502 | 0.00 | — | 112,558 | — | ↗ |
| 2022-07-05 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,046 | 0.00 | — | 137,187 | — | ↗ |
| 2022-06-24 | Thompson Peter A. | Director | A-Award | A | Stock Option (Right to Buy) | 42,087 | 0.00 | — | 42,087 | — | ↗ |
| 2022-06-24 | ROOT JONATHAN D | Director | A-Award | A | Stock Option (Right to Buy) | 42,087 | 8.53 | 359.0K | 42,087 | — | ↗ |
| 2022-06-24 | Edris Badreddin | Director | A-Award | A | Stock Option (Right to Buy) | 42,087 | 8.53 | 359.0K | 42,087 | — | ↗ |
| 2022-06-24 | Brege Laura | Director | A-Award | A | Stock Option (Right to Buy) | 42,087 | 8.53 | 359.0K | 42,087 | — | ↗ |
| 2022-06-16 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 17,570 | 0.00 | — | 141,917 | — | ↗ |
| 2022-06-13 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 585 | 0.00 | — | 196,336 | — | ↗ |
| 2022-06-08 | MOORE JOHN R | Director | S-Sale | D | Common Stock | 7,125 | 6.05 | 43.1K | 3,000 | — | ↗ |
| 2022-06-03 | MOORE JOHN R | Director | M-Exempt | D | Stock Option (Right to Buy) | 13,934 | 0.00 | — | 197,894 | — | ↗ |
| 2022-05-23 | Carruthers R Michael | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,000 | 0.71 | 6.4K | 207,122 | — | ↗ |
| 2022-05-18 | Thompson Peter A. | Director | P-Purchase | A | Common Stock | 138,000 | 7.21 | 995.0K | 13,497,456 | — | ↗ |
| 2022-05-18 | OrbiMed Genesis GP LLC | Director | P-Purchase | A | Common Stock | 138,000 | 7.21 | 995.0K | 13,497,456 | — | ↗ |
| 2022-05-18 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 138,000 | 7.21 | 995.0K | 13,497,456 | — | ↗ |
| 2022-05-16 | MOORE JOHN R | Director | S-Sale | D | Common Stock | 10,800 | 7.42 | 80.1K | 3,000 | — | ↗ |
| 2022-05-01 | Russell Alan J | Director / Officer | A-Award | A | Restricted Stock Units | 15,625 | 0.00 | — | 15,625 | — | ↗ |
| 2022-05-01 | MOORE JOHN R | Director | A-Award | A | Restricted Stock Units | 15,625 | 0.00 | — | 15,625 | — | ↗ |
| 2022-05-01 | KOCH KEVIN | Director | A-Award | A | Restricted Stock Units | 31,250 | 0.00 | — | 31,250 | — | ↗ |
| 2022-05-01 | Donovan Joanne M. | Director | A-Award | A | Restricted Stock Units | 31,250 | 0.00 | — | 31,250 | — | ↗ |
| 2022-05-01 | Derakhshan Behrad | Director / Officer | A-Award | A | Restricted Stock Units | 15,625 | 0.00 | — | 15,625 | — | ↗ |
| 2022-05-01 | Carruthers R Michael | Director / Officer | A-Award | A | Restricted Stock Units | 15,625 | 0.00 | — | 15,625 | — | ↗ |
| 2022-02-25 | ROOT JONATHAN D | Director | J-Other | D | Common Stock | 3,473,543 | 0.00 | — | 0 | — | ↗ |
| 2022-01-21 | MOORE JOHN R | — | M-Exempt | D | Stock Option (Right to Buy) | 5,400 | 0.71 | 3.8K | 205,322 | — | ↗ |
| 2021-12-28 | MOORE JOHN R | — | M-Exempt | D | Stock Option (Right to Buy) | 5,400 | 0.71 | 3.8K | 210,722 | — | ↗ |
| 2021-11-30 | Russell Alan J | — | M-Exempt | A | Common Stock | 25,000 | 0.45 | 11.3K | 172,585 | — | ↗ |
| 2021-11-15 | Russell Alan J | — | S-Sale | D | Common Stock | 441 | 19.07 | 8.4K | 38 | — | ↗ |
| 2021-11-12 | Russell Alan J | — | S-Sale | D | Common Stock | 8,562 | 19.51 | 167.1K | 479 | — | ↗ |
| 2021-11-11 | Russell Alan J | — | S-Sale | D | Common Stock | 15,595 | 19.82 | 309.0K | 12,722 | — | ↗ |
| 2021-11-10 | Russell Alan J | — | S-Sale | D | Common Stock | 580 | 20.21 | 11.7K | 28,317 | — | ↗ |
| 2021-11-09 | Russell Alan J | — | S-Sale | D | Common Stock | 12,712 | 20.30 | 258.0K | 40,643 | — | ↗ |
| 2021-11-08 | Russell Alan J | — | S-Sale | D | Common Stock | 9,017 | 20.16 | 181.8K | 70,219 | — | ↗ |
| 2021-11-05 | Russell Alan J | — | S-Sale | D | Common Stock | 6 | 20.70 | 124.20 | 92,272 | — | ↗ |
| 2021-11-04 | Russell Alan J | — | S-Sale | D | Common Stock | 7,392 | 19.76 | 146.1K | 92,278 | — | ↗ |
| 2021-11-03 | Russell Alan J | — | S-Sale | D | Common Stock | 20,822 | 17.98 | 374.4K | 105,032 | — | ↗ |
| 2021-11-02 | Russell Alan J | — | S-Sale | D | Common Stock | 17,519 | 17.43 | 305.4K | 125,854 | — | ↗ |
| 2021-11-01 | Russell Alan J | — | S-Sale | D | Common Stock | 469 | 18.02 | 8.5K | 143,373 | — | ↗ |
| 2021-10-15 | Russell Alan J | — | S-Sale | D | Common Stock | 126 | 18.00 | 2.3K | 143,842 | — | ↗ |
| 2021-10-14 | Russell Alan J | — | S-Sale | D | Common Stock | 5,749 | 18.18 | 104.5K | 145,275 | — | ↗ |
| 2021-10-11 | Russell Alan J | — | S-Sale | D | Common Stock | 1,270 | 18.02 | 22.9K | 151,024 | — | ↗ |
| 2021-10-08 | Russell Alan J | — | S-Sale | D | Common Stock | 5,902 | 18.15 | 107.1K | 152,294 | — | ↗ |
| 2021-10-07 | Russell Alan J | — | S-Sale | D | Common Stock | 13,018 | 18.56 | 241.6K | 158,196 | — | ↗ |
| 2021-10-06 | Russell Alan J | — | S-Sale | D | Common Stock | 2,108 | 18.03 | 38.0K | 171,214 | — | ↗ |
| 2021-10-05 | Russell Alan J | — | S-Sale | D | Common Stock | 5,404 | 18.26 | 98.7K | 173,322 | — | ↗ |
| 2021-10-04 | Russell Alan J | — | S-Sale | D | Common Stock | 100 | 18.00 | 1.8K | 178,726 | — | ↗ |
| 2021-10-01 | Russell Alan J | — | S-Sale | D | Common Stock | 274 | 18.00 | 4.9K | 178,826 | — | ↗ |
| 2021-09-29 | Russell Alan J | — | S-Sale | D | Common Stock | 11,226 | 16.83 | 188.9K | 179,718 | — | ↗ |
| 2021-09-28 | Russell Alan J | — | S-Sale | D | Common Stock | 14,610 | 17.30 | 252.8K | 190,944 | — | ↗ |
| 2021-09-27 | Russell Alan J | — | S-Sale | D | Common Stock | 11,594 | 17.98 | 208.5K | 205,571 | — | ↗ |
| 2021-09-24 | Russell Alan J | — | S-Sale | D | Common Stock | 20,100 | 18.16 | 365.0K | 217,165 | — | ↗ |
| 2021-09-23 | Russell Alan J | — | S-Sale | D | Common Stock | 5,072 | 19.42 | 98.5K | 237,265 | — | ↗ |
| 2021-08-17 | Russell Alan J | — | A-Award | A | Stock Option (Right to Buy) | 120,000 | 16.38 | 1.97M | 120,000 | — | ↗ |
| 2021-08-17 | MOORE JOHN R | — | A-Award | A | Stock Option (Right to Buy) | 120,000 | 16.38 | 1.97M | 120,000 | — | ↗ |
| 2021-08-17 | KOCH KEVIN | — | A-Award | A | Stock Option (Right to Buy) | 400,000 | 16.38 | 6.55M | 400,000 | — | ↗ |
| 2021-08-17 | Donovan Joanne M. | — | A-Award | A | Stock Option (Right to Buy) | 160,000 | 16.38 | 2.62M | 160,000 | — | ↗ |
| 2021-08-17 | Derakhshan Behrad | — | A-Award | A | Stock Option (Right to Buy) | 140,000 | 16.38 | 2.29M | 140,000 | — | ↗ |
| 2021-08-17 | Carruthers R Michael | — | A-Award | A | Stock Option (Right to Buy) | 120,000 | 16.38 | 1.97M | 120,000 | — | ↗ |
| 2021-04-30 | Donovan Joanne M. | — | A-Award | A | Stock Option (Right to Buy) | 160,000 | 28.64 | 4.58M | 160,000 | — | ↗ |
| 2021-04-26 | Donovan Joanne M. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-30 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | C-Conversion | A | Common Stock | 681,812 | 0.00 | — | 681,812 | — | ↗ |
| 2021-03-30 | Thompson Peter A. | Director / 10% Owner | C-Conversion | D | Series C Preferred Stock | 272,724 | 0.00 | — | 0 | — | ↗ |
| 2021-03-30 | ROOT JONATHAN D | Director | C-Conversion | A | Common Stock | 3,473,543 | 0.00 | — | 3,473,543 | — | ↗ |
Executive team
Top executives
Shares Outstanding
107.27M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Kevin Koch, Ph.D. President and Chief Executive Officer | 670.0K | — | 1.17M | 5.04M | 462.3K | 14.0K | 7.36M | 84.42% | ↗ |
| 2 | 2025 | Former Chief Development Officer | 525.0K | — | 999.5K | 2.80M | 227.6K | 14.0K | 4.57M | 83.22% | ↗ |
| 3 | 2025 | Chief Financial Officer | 67.8K | — | 799.8K | 3.39M | 29.9K | — | 4.28M | 97.72% | ↗ |
| 4 | 2025 | Behrad Derakhshan, Ph.D. Chief Operating Officer | 520.0K | — | 401.7K | 1.73M | 269.1K | 14.0K | 2.93M | 72.62% | ↗ |
| 5 | 2025 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 530.4K | — | 376.6K | 1.62M | 244.0K | 14.0K | 2.79M | 71.70% | ↗ |
| 6 | 2025 | Co-Founder and | 499.6K | — | 376.6K | 1.62M | 229.8K | 8.5K | 2.73M | 73.02% | ↗ |
| 7 | 2025 | Former Chief Financial Officer | 465.7K | — | 392.7K | 1.50M | 214.2K | 14.0K | 2.59M | 73.18% | ↗ |
| 8 | 2024 | Kevin Koch, Ph.D. President and Chief Executive Officer | 618.7K | — | 1.23M | 5.30M | 442.4K | 13.8K | 7.60M | 85.86% | ↗ |
| 9 | 2024 | Kevin Koch, Ph.D. President and Chief Executive Officer | 618.7K | — | 1.23M | 5.30M | 442.4K | 13.8K | 7.60M | 85.86% | ↗ |
| 10 | 2024 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 507.5K | — | 394.3K | 1.71M | 303.5K | 13.8K | 2.92M | 71.80% | ↗ |
| 11 | 2024 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 507.5K | — | 394.3K | 1.71M | 303.5K | 13.8K | 2.92M | 71.80% | ↗ |
| 12 | 2024 | Behrad Derakhshan, Ph.D. Chief Operating Officer | 478.4K | — | 394.3K | 1.71M | 311.0K | 7.2K | 2.90M | 72.50% | ↗ |
| 13 | 2024 | Behrad Derakhshan, Ph.D. Chief Operating Officer | 478.4K | — | 394.3K | 1.71M | 311.0K | 7.2K | 2.90M | 72.50% | ↗ |
| 14 | 2023 | Kevin Koch, Ph.D. President and Chief Executive Officer | 594.9K | — | — | 3.07M | 297.4K | 13.2K | 3.98M | 77.22% | ↗ |
| 15 | 2023 | Kevin Koch, Ph.D. President and Chief Executive Officer | 594.9K | — | — | 3.07M | 297.4K | 13.2K | 3.98M | 77.22% | ↗ |
| 16 | 2023 | Behrad Derakhshan, Ph.D. Chief Business Officer | 446.7K | — | — | 1.13M | 184.0K | — | 1.76M | 64.09% | ↗ |
| 17 | 2023 | Behrad Derakhshan, Ph.D. Chief Operating Officer | 446.7K | — | — | 1.13M | 184.0K | — | 1.76M | 64.09% | ↗ |
| 18 | 2023 | Behrad Derakhshan, Ph.D. Chief Operating Officer | 446.7K | — | — | 1.13M | 184.0K | — | 1.76M | 64.09% | ↗ |
| 19 | 2023 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 488.0K | — | — | 1.02M | 195.2K | 13.2K | 1.72M | 59.44% | ↗ |
| 20 | 2023 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 488.0K | — | — | 1.02M | 195.2K | 13.2K | 1.72M | 59.44% | ↗ |
| 21 | 2022 | Kevin Koch, Ph.D. President and Chief Executive Officer | 572.0K | — | 249.4K | 4.19M | 328.9K | 12.2K | 5.36M | 82.95% | ↗ |
| 22 | 2022 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 468.0K | — | 249.4K | 1.83M | 215.3K | 12.2K | 2.77M | 74.93% | ↗ |
| 23 | 2022 | Alan J. Russell, Ph.D. Co-Founder and Chief Scientific Officer | 442.0K | — | 124.7K | 1.68M | 203.3K | 12.2K | 2.46M | 73.26% | ↗ |
| 24 | 2022 | Behrad Derakhshan, Ph.D. Chief Business Officer | 416.0K | — | 124.7K | 1.52M | 191.4K | — | 2.26M | 73.09% | ↗ |
| 25 | 2021 | Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | 308.5K | — | — | 4.72M | 141.2K | 3.8K | 5.17M | 91.23% | ↗ |
| 26 | 2021 | Kevin Koch, Ph.D. President and Chief Executive Officer | 524.5K | — | — | 4.27M | 316.3K | 4.6K | 5.12M | 83.48% | ↗ |
| 27 | 2021 | Behrad Derakhshan, Ph.D. Chief Business Officer | 388.2K | — | — | 1.50M | 184.0K | 3.3K | 2.07M | 72.21% | ↗ |
| 28 | 2021 | Alan J. Russell, Ph.D. Co-Founder and Chief Scientific Officer | 410.6K | — | — | 1.28M | 195.5K | 3.5K | 1.89M | 67.77% | ↗ |
| 29 | 2020 | Kevin Koch, Ph.D. President and Chief Executive Officer | 425.0K | — | — | 1.01M | 255.0K | — | 1.69M | 59.76% | ↗ |
| 30 | 2020 | Behrad Derakhshan, Ph.D. Chief Business Officer | 110.8K | — | — | 330.1K | 36.3K | — | 477.2K | 69.17% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kevin Koch | President, Chief Executive Officer & Director | 1M | — |
| Behrad Derakhshan | Chief Operating Officer | 803.1K | — |
| Joanne Donovan | Chief Medical Officer | 788.3K | — |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director | 737.9K | — |
| Michael Nofi | Chief Financial Officer | 97.7K | male |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman | 80.0K | — |
| Badreddin Edris | Co-Founder & Independent Director | 55.0K | — |
| Robert Blaustein | Chief Development Officer | — | — |
| John R. Moore | General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EWTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
